Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	26.06	91.14	143.99	108.03	149.95	56.88
Short-Term Investments	-	60.47	2.95	96.57	219.63	311.34
Cash & Short-Term Investments	26.06	151.61	146.94	204.61	369.58	368.22
Cash Growth	-87.87%	3.18%	-28.18%	-44.64%	0.37%	311.22%
Accounts Receivable	9.31	1.45	0.82	7.44	0.75	0.14
Other Receivables	19.58	14.53	46.1	30.65	33.26	20.95
Receivables	28.9	15.98	46.92	38.09	34.01	21.09
Inventory	11.41	7.38	1.33	1.28	0.75	2.09
Prepaid Expenses	8.23	10.03	9.95	9.47	9.04	6.31
Other Current Assets	3.52	3.17	2.41	1.93	2.08	0.44
Total Current Assets	78.12	188.17	207.55	255.37	415.46	398.15
Property, Plant & Equipment	46.9	51.22	71.71	71.54	51.37	46.66
Other Intangible Assets	3.81	3.88	0.33	0.44	1	1.73
Other Long-Term Assets	1.81	2.7	3.03	1.57	1.72	4.6
Total Assets	130.63	245.96	282.62	328.92	469.55	451.14
Accounts Payable	9.42	8.69	8.13	4.75	8.11	6.39
Accrued Expenses	22.54	30.9	28.85	29.06	29.58	27.03
Current Portion of Leases	4.51	4.71	5.38	2.73	2.32	2.77
Current Income Taxes Payable	-	-	1.4	-	-	-
Current Unearned Revenue	10.7	12.3	28.97	23.52	22.2	2.83
Other Current Liabilities	4.34	7.93	0.05	4.44	0.33	0.05
Total Current Liabilities	51.51	64.53	72.79	64.5	62.54	39.07
Long-Term Debt	25.68	50.24	-	-	-	-
Long-Term Leases	18.49	19.26	19.85	20.35	23.15	20.94
Long-Term Unearned Revenue	101.42	95.82	149.06	160.89	177.22	49.26
Other Long-Term Liabilities	4.49	4.27	1.4	1.3	0.67	0.64
Total Liabilities	201.59	234.11	243.1	247.04	263.59	109.92
Common Stock	2.16	2.09	1.87	1.4	1.34	1.33
Additional Paid-In Capital	1,109	1,106	1,065	990.66	959.61	935.71
Retained Earnings	-1,172	-1,094	-1,023	-909.3	-743.85	-585.76
Comprehensive Income & Other	-10.61	-1.9	-3.75	-0.88	-11.14	-10.05
Shareholders' Equity	-70.96	11.85	39.51	81.88	205.96	341.23
Total Liabilities & Equity	130.63	245.96	282.62	328.92	469.55	451.14
Total Debt	48.68	74.21	25.24	23.08	25.47	23.71
Net Cash (Debt)	-22.62	77.4	121.7	181.53	344.11	344.51
Net Cash Growth	-	-36.41%	-32.96%	-47.25%	-0.11%	437.59%
Net Cash Per Share	-0.09	0.31	0.61	1.13	2.21	2.42
Filing Date Shares Outstanding	265.05	257.23	246.83	165.31	156.73	155.14
Total Common Shares Outstanding	265.05	255.94	227.17	164.52	156.26	154.79
Working Capital	26.6	123.64	134.76	190.87	352.92	359.08
Book Value Per Share	-0.27	0.05	0.17	0.50	1.32	2.20
Tangible Book Value	-74.77	7.97	39.18	81.44	204.96	339.5
Tangible Book Value Per Share	-0.28	0.03	0.17	0.49	1.31	2.19
Machinery	-	39.91	38.97	34.92	32.65	30.52
Construction In Progress	-	0.28	0.05	28.73	5.4	-
Leasehold Improvements	-	43.01	57.94	28.46	28.7	28.36

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q